Cadrenal Therapeutics (CVKD) Stock Analysis
NASDAQHealthcareBiotechnology
What Cadrenal Therapeutics does
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Key metrics
ETFs linked to CVKD
Broad-market and Healthcare sector ETFs an investor holding Cadrenal Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how CVKD fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze CVKD in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Cadrenal Therapeutics?
- Cadrenal Therapeutics trades under the ticker CVKD on NASDAQ.
- Which exchange is CVKD listed on?
- CVKD is listed on NASDAQ.
- What sector does Cadrenal Therapeutics operate in?
- Cadrenal Therapeutics is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze CVKD in a portfolio?
- PortView shows CVKD's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.